A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

This phase 1 study investigated the recommended phase 2 dose (RP2D) of inotuzumab ozogamicin (InO), a CD22-directed antibody-drug conjugate, in pediatric patients with multiple relapsed/refractory (R/R) CD22+ acute lymphoblastic leukemia (ALL). Patients (age ≥1 year or

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2021-03, Vol.137 (12), p.1582-1590
Hauptverfasser: Brivio, Erica, Locatelli, Franco, Lopez-Yurda, Marta, Malone, Andrea, Díaz-de-Heredia, Cristina, Bielorai, Bella, Rossig, Claudia, van der Velden, Vincent H.J., Ammerlaan, Anneke C.J., Thano, Adriana, van der Sluis, Inge M., den Boer, Monique L., Chen, Ying, Sleight, Barbara, Brethon, Benoit, Nysom, Karsten, Sramkova, Lucie, Øra, Ingrid, Vinti, Luciana, Chen-Santel, Christiane, Zwaan, Christian Michel
Format: Artikel
Sprache:eng
Schlagworte:
Clinical Trials and Observations
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This phase 1 study investigated the recommended phase 2 dose (RP2D) of inotuzumab ozogamicin (InO), a CD22-directed antibody-drug conjugate, in pediatric patients with multiple relapsed/refractory (R/R) CD22+ acute lymphoblastic leukemia (ALL). Patients (age ≥1 year or
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.2020007848